{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:38:44Z","timestamp":1791232724699,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":157,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the EMPACT-MI trial, empagliflozin did not reduce the primary endpoint of all-cause mortality or hospitalization for heart failure (HHF) following acute myocardial infarction (AMI) but was associated with a risk reduction for HF events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate whether the effect of empagliflozin on HF events is consistent in patients with and without type 2 diabetes and\/or chronic kidney disease enrolled in the EMPACT-MI trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc analysis assessing the effect of empagliflozin on the primary endpoint and on HF events in AMI patients with and without an established recommendation for a sodium\u2013glucose cotransporter-2 inhibitor (SGLT2i) (type 2 diabetes or chronic kidney disease).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 6522 participants, 3489 (53%) did not have type 2 diabetes and\/or chronic kidney disease. Those without these conditions were younger and with fewer comorbidities. No differences were observed for the primary endpoint. Empagliflozin reduced time to first HHF, total HHF, time to adverse event (AE) of HF (including outpatient HF events) and total AEs of HF similarly in patients with and without type 2 diabetes or chronic kidney disease. Total HHFs were 50 and 63 [adjusted event rate 1.74 and 2.31 events per 100 patient-years; rate ratio (RR) 0.75; 95% confidence interval (CI) 0.48, 1.18] in patients without and 98 and 144 (adjusted event rate 3.91 and 6.04 events per 100 patient-years; RR 0.65; 95% CI 0.45, 0.94; P for interaction = 0.61) in those with type 2 diabetes or chronic kidney disease in the empagliflozin and placebo arms, respectively. Any AEs, serious AEs and AEs leading to permanent study drug discontinuation were similar between treatment groups in both subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Empagliflozin improved HF outcomes similarly in patients after AMI with or without type 2 diabetes or chronic kidney disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15393","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:57:49Z","timestamp":1757919469000},"page":"3940-3952","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI"],"prefix":"10.1093","volume":"12","author":[{"given":"Francesco","family":"Fioretti","sequence":"first","affiliation":[{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]},{"name":"Cardiology Unit, ASST Spedali Civili Hospital and University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute , Dallas, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Women's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Schuyler Jones","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG , Ingelheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hanover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"Heart Institute, Hospital Universitari Germans Trias i Pujol , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton ,","place":["Canada"]},{"name":"Division of Cardiology, Department of Medicine, St. Michael's Hospital, Unity Health Toronto and Peter Munk Cardiac Centre, University Health Network, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Gasior","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim ,","place":["Germany"]},{"name":"Collegium Medicum\u2014Faculty of Medicine, WSB University , D\u0105browa G\u00f3rnicza ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Baim Institute for Clinical Research , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute for Heart Diseases, Wroc\u0142aw Medical University , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rossello","sequence":"additional","affiliation":[{"name":"Hospital Universitari Son Espases, Health Research Institute of the Balearic Islands, University of the Balearic Islands , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte University Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[{"name":"University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Max Rady College of Medicine, University of Manitoba , Winnipeg ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim ,","place":["Germany"]},{"name":"First Department of Medicine, Medical Faculty Mannheim, Heidelberg University , Mannheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Sumin","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK), German Heart Center Charit\u00e9, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"2026021804144002900_ehf215393-bib-0001","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jchf.2022.02.008","article-title":"Acute decompensated heart failure in the setting of acute coronary syndrome","volume":"10","author":"Harrington","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0002","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","article-title":"Left ventricular remodelling post-myocardial infarction: Pathophysiology, imaging, and novel therapies","volume":"43","author":"Frantz","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804144002900_ehf215393-bib-0003","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ejhf.3225","article-title":"Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention","volume":"26","author":"Lenselink","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0004","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3550","article-title":"The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries\u2014A Global Congestive Heart Failure (G-CHF) study","author":"Leong","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0005","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ejhf.3548","article-title":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial","volume":"27","author":"Petrie","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0006","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ejhf.3602","article-title":"Failure to improve cardiac remodelling and outcomes post-myocardial infarction: Insights from EMPRESS-MI","volume":"27","author":"Fioretti","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0007","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021804144002900_ehf215393-bib-0008","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804144002900_ehf215393-bib-0009","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804144002900_ehf215393-bib-0010","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/circulationaha.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: Insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026021804144002900_ehf215393-bib-0011","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804144002900_ehf215393-bib-0012","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/cir.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804144002900_ehf215393-bib-0013","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0014","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","volume":"253","author":"Harrington","year":"2022","journal-title":"Am Heart J"},{"key":"2026021804144002900_ehf215393-bib-0015","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.rec.2021.06.003","article-title":"Survival analyses in cardiovascular research, part I: The essentials","volume":"75","author":"Rossello","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026021804144002900_ehf215393-bib-0016","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.rec.2021.07.001","article-title":"Survival analyses in cardiovascular research, part II: Statistical methods in challenging situations","volume":"75","author":"Rossello","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026021804144002900_ehf215393-bib-0017","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2024.03.405","article-title":"Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction","volume":"83","author":"Udell","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804144002900_ehf215393-bib-0018","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0019","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021804144002900_ehf215393-bib-0020","doi-asserted-by":"publisher","first-page":"L38","DOI":"10.1093\/eurheartjsupp\/suac120","article-title":"Getting ahead of the game: In-hospital initiation of HFrEF therapies","volume":"24","author":"Biegus","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2026021804144002900_ehf215393-bib-0021","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.08","article-title":"In-hospital initiation and up-titration of guideline-directed medical therapies for heart failure with reduced ejection fraction","volume":"8","author":"Cox","year":"2022","journal-title":"Card Fail Rev"},{"key":"2026021804144002900_ehf215393-bib-0022","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/ehjqcco\/qcad007","article-title":"Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines","volume":"9","author":"Mas-Llado","year":"2023","journal-title":"Eur Heart J Qual Care Clin Outc"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3940\/66967948\/eschf_12_6_3940.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/3940\/66967948\/eschf_12_6_3940.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:14:50Z","timestamp":1771406090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/3940\/8488154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,14]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15393","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,14]]},"assertion":[{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}